Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates

Prostate Cancer and Prostatic Diseases volume 11, pages 13–19 (2008)Cite this article

Abstract

Androgen-deprivation therapy, a mainstay in the treatment of locally advanced and metastatic prostate cancer, is associated with significant bone loss and related complications, such as fracture. Bisphosphonates, osteoclast inhibitors, are effective in preventing skeletal-related events in patients with metastatic prostate cancer and also in preventing bone loss in patients with locally advanced disease. Understanding the management of bone health, including identifying patients at risk, the most appropriate therapy, and monitoring and managing side effects, is critical. This review provides the most recent bone health risk factor and bisphosphonate data available for prostate cancer patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248–1253.

    Article  CAS  PubMed  Google Scholar 

  2. Casey R, Love W, Mendoza C, Reymond D, Zarenda M . Zoledronic acid reduces bone loss in men with prostate cancer undergoing androgen deprivation therapy. The 2006 Multidisciplinary Prostate Cancer Symposium, 24–26 February 2006; San Francisco, Calif. Abstract 184.

  3. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038–1042.

    Article  CAS  PubMed  Google Scholar 

  4. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008–2012.

    Article  CAS  PubMed  Google Scholar 

  5. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Shoenfeld DA et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948–955.

    Article  CAS  PubMed  Google Scholar 

  6. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV, the Zometa US05 Investigators. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006; 176: 972–978.

    Article  CAS  PubMed  Google Scholar 

  7. Israeli RS, Rosenberg S, Saltzstein D, Gottesman JE, Goldstein HR, Hull GW et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen-deprivation therapy. Clin Genitourin Cancer 2007; 5: 271–277.

    Article  CAS  PubMed  Google Scholar 

  8. Higano CS . Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004; 31: 331–352.

    Article  PubMed  Google Scholar 

  9. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS . Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154–164.

    Article  CAS  PubMed  Google Scholar 

  10. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Phashos CL . Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897–7903.

    Article  CAS  PubMed  Google Scholar 

  11. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J . Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175: 136–139.

    Article  CAS  PubMed  Google Scholar 

  12. Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ . Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 2004; 64: 335–340.

    Article  PubMed  Google Scholar 

  13. Agarwal MM, Khandelwal N, Mandal AK, Rana SV, Gupta V, Chandra Mohan V et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchiectomy. Cancer 2005; 103: 2042–2052.

    Article  PubMed  Google Scholar 

  14. Kiratli J, Srinivas S, Perkash I, Terris MK . Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127–132.

    Article  CAS  PubMed  Google Scholar 

  15. Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT . Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 2007; 70: 122–126.

    Article  PubMed  Google Scholar 

  16. Morote J, Martinez E, Trilla E, Esquena S, Abascal JM, Encabo G et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 2003; 44: 661–665.

    Article  CAS  PubMed  Google Scholar 

  17. Wegner H . Clinical experience with zoledronic acid: a urologist's perspective. Eur Urol Suppl 2006; 5: 551–552.

    Article  Google Scholar 

  18. Lipton A . Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2004; 2: 205–213.

    PubMed  Google Scholar 

  19. Greenspan SL, Nelson JB, Trump DL, Resnick NM . Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416–424.

    Article  PubMed  Google Scholar 

  20. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–1468.

    Article  CAS  PubMed  Google Scholar 

  21. Saad F, Gleason DM, Murray R, Techkmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–882.

    Article  CAS  PubMed  Google Scholar 

  22. Zometa® (package insert). Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2006.

  23. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604–610.

    Article  CAS  PubMed  Google Scholar 

  24. Ringe JD, Faber H, Dorst A . Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001; 86: 5252–5255.

    Article  CAS  PubMed  Google Scholar 

  25. Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 2006; 4: 257–262.

    Article  CAS  PubMed  Google Scholar 

  26. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO . Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21: 4277–4284.

    Article  CAS  PubMed  Google Scholar 

  27. Eastham J, McKiernan J, Gleason D, Zheng M, Saad F . Effect of zoledronic acid on bone pain and skeletal morbidity in patients with advanced prostate cancer; analysis by baseline pain. J Clin Oncol 2005; 23 (16S): 393s. Abstract 4561.

    Google Scholar 

  28. Berenson JR . Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10: 52–62.

    Article  CAS  PubMed  Google Scholar 

  29. Polascik TJ, Given RW, Metzer C, Julan SR, Vestal JC, Karlin GS et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005; 66: 1054–1059.

    Article  PubMed  Google Scholar 

  30. National Comprehensive Cancer Network Inc. The NCCN (2.2005) Prostate Cancer Clinical Practice Guidelines in Oncology 2006. Available at: http://www.nccn.org. Accessed on 10 October 2006. To view the most recent and complete version of the guideline, go online to www.nccn.org.

  31. Fosamax® (package insert). Merck & Co, Inc: Whitehouse Station, NJ, 2006.

  32. Ruggerio S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2: 7–14.

    Article  Google Scholar 

  33. Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006; 24: 475S. Abstract 8528.

    Google Scholar 

Download references

Acknowledgements

We thank Syntaxx Communications Inc. who provided editorial services on behalf of Novartis Oncology.

Author information

Authors and Affiliations

  1. Duke Prostate Center and Division of Urologic Surgery, Duke University, Durham, NC, USA

    T J Polascik

Authors
  1. T J Polascik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T J Polascik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Polascik, T. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. Prostate Cancer Prostatic Dis 11, 13–19 (2008). https://doi.org/10.1038/sj.pcan.4501019

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4501019

Keywords

This article is cited by

Search

Advanced search

Quick links